<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id><journal-id journal-id-type="iso-abbrev">Med. Sci. Monit</journal-id><journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id><journal-title-group><journal-title>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research</journal-title></journal-title-group><issn pub-type="ppub">1234-1010</issn><issn pub-type="epub">1643-3750</issn><publisher><publisher-name>International Scientific Literature, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26965791</article-id><article-id pub-id-type="pmc">4791088</article-id><article-id pub-id-type="doi">10.12659/MSM.895749</article-id><article-id pub-id-type="publisher-id">895749</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Comparison of Prednisolone, Etoricoxib, and Indomethacin in Treatment of Acute Gouty Arthritis: An Open-Label, Randomized, Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Lingling</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-22-810">A</xref><xref ref-type="author-notes" rid="fn4-medscimonit-22-810">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-22-810">E</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shiqun</given-names></name><xref ref-type="author-notes" rid="fn2-medscimonit-22-810">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-22-810">C</xref><xref ref-type="author-notes" rid="fn5-medscimonit-22-810">E</xref></contrib><contrib contrib-type="author"><name><surname>Guan</surname><given-names>Meiping</given-names></name><xref ref-type="author-notes" rid="fn2-medscimonit-22-810">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-22-810">C</xref><xref ref-type="author-notes" rid="fn5-medscimonit-22-810">E</xref></contrib><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Yaoming</given-names></name><xref ref-type="author-notes" rid="fn1-medscimonit-22-810">A</xref><xref ref-type="author-notes" rid="fn2-medscimonit-22-810">B</xref><xref ref-type="author-notes" rid="fn4-medscimonit-22-810">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-22-810">E</xref><xref ref-type="corresp" rid="c1-medscimonit-22-810"/></contrib><aff id="af1-medscimonit-22-810">Department of Endocrinology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P.R. China</aff></contrib-group><author-notes><corresp id="c1-medscimonit-22-810">Corresponding Author: Yaoming Xue, e-mail: <email>yaomingxue123@yeah.net</email></corresp><fn id="fn1-medscimonit-22-810"><label>A</label><p>Study Design</p></fn><fn id="fn2-medscimonit-22-810"><label>B</label><p>Data Collection</p></fn><fn id="fn3-medscimonit-22-810"><label>C</label><p>Statistical Analysis</p></fn><fn id="fn4-medscimonit-22-810"><label>D</label><p>Data Interpretation</p></fn><fn id="fn5-medscimonit-22-810"><label>E</label><p>Manuscript Preparation</p></fn><fn id="fn6-medscimonit-22-810"><label>F</label><p>Literature Search</p></fn><fn id="fn7-medscimonit-22-810"><label>G</label><p>Funds Collection</p></fn></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>11</day><month>3</month><year>2016</year></pub-date><volume>22</volume><fpage>810</fpage><lpage>817</lpage><history><date date-type="received"><day>24</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>21</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Med Sci Monit, 2016</copyright-statement><copyright-year>2016</copyright-year><license><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</license-p></license></permissions><abstract><sec><title>Background</title><p>At present there are several kinds of medicine for treating acute gout arthritis (AGA). This study compared the efficacy and safety of prednisolone, etoricoxib, and indomethacin in the treatment of AGA.</p></sec><sec><title>Material/Methods</title><p>This was an open-label, randomized, active-comparator study in patients with AGA. Patients were randomized to 4 days of prednisolone 35 mg qd, etoricoxib 120 mg qd, or indomethacin 50 mg tid. The primary efficacy endpoint was the reduction of self-assessed pain in the index joint from baseline. Secondary endpoints included changes in physician&#x02019;s assessment of tenderness, erythema, swelling, and joint activity; patient assessment of response to therapy; and safety.</p></sec><sec><title>Results</title><p>We analyzed 113 patients. Baseline demographics were comparable among treatment groups. Oral prednisolone, etoricoxib, and indomethacin were similarly effective in improving pain, tenderness, and joint activity over 4 days. For inflammation, oral prednisolone, etoricoxib, and indomethacin were similarly effective in reducing erythema, but prednisolone might be more effective in reducing swelling than indomethacin. The patient response to therapy was similar in the 3 groups. There were more total adverse events with indomethacin compared with the other 2 drugs.</p></sec><sec><title>Conclusions</title><p>Efficacy was comparable among prednisolone, etoricoxib, and indomethacin for the treatment of AGA. Prednisolone might be more effective in reducing inflammation and it had a better safety profile.</p></sec></abstract><kwd-group><title>MeSH Keywords</title><kwd>Arthritis</kwd><kwd>Arthritis, Gouty</kwd><kwd>Indomethacin</kwd><kwd>Inflammation</kwd><kwd>Prednisolone</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Gouty arthritis is the most common inflammatory joint disease in men aged &#x0003e;40 years [<xref rid="b1-medscimonit-22-810" ref-type="bibr">1</xref>], with an overall global age-standardized prevalence of 0.08%, or 0.13% in men and 0.03% in women [<xref rid="b2-medscimonit-22-810" ref-type="bibr">2</xref>]. Gouty arthritis is a joint disease caused by deposition of monosodium urate, associated with purine metabolic disorder [<xref rid="b3-medscimonit-22-810" ref-type="bibr">3</xref>&#x02013;<xref rid="b5-medscimonit-22-810" ref-type="bibr">5</xref>]. The progress of gout generally consists of 3 stages: hyperuricemia without symptoms, gout attacks with intermittent periods without symptoms, and long-term chronic gout without remission [<xref rid="b6-medscimonit-22-810" ref-type="bibr">6</xref>]. Gout itself may be disabling [<xref rid="b7-medscimonit-22-810" ref-type="bibr">7</xref>], as hyperuricemia may lead to renal failure [<xref rid="b3-medscimonit-22-810" ref-type="bibr">3</xref>]. Although pain may be the first complaint of patients with gout, an effective treatment should take into account both pain and potential inflammation [<xref rid="b8-medscimonit-22-810" ref-type="bibr">8</xref>,<xref rid="b9-medscimonit-22-810" ref-type="bibr">9</xref>]. The specific mechanisms leading to the inflammatory response of gouty arthritis are not fully understood. A study [<xref rid="b10-medscimonit-22-810" ref-type="bibr">10</xref>] found that the environmental toxin 4-Nonylphenol may promote an inflammatory response in inflammatory bowel disease, but whether it plays a role in the inflammatory response of the gout arthritis is not clear.</p><p>At present, non-steroidal anti-inflammatory drugs (NSAIDs) are the main treatment for gout, and these drugs are not only used for analgesia, but also for inhibiting inflammation [<xref rid="b3-medscimonit-22-810" ref-type="bibr">3</xref>,<xref rid="b11-medscimonit-22-810" ref-type="bibr">11</xref>]. The effect of indomethacin in the treatment of AGA is generally accepted, and its common dosage is 50 mg 3 times a day [<xref rid="b12-medscimonit-22-810" ref-type="bibr">12</xref>]. Although the tolerance of indomethacin is not good, it is still the criterion standard drug for the treatment of AGA [<xref rid="b3-medscimonit-22-810" ref-type="bibr">3</xref>]. However, many clinical studies found that indomethacin has various adverse effects (AEs) [<xref rid="b13-medscimonit-22-810" ref-type="bibr">13</xref>&#x02013;<xref rid="b16-medscimonit-22-810" ref-type="bibr">16</xref>], and the gastrointestinal (GI) tract AEs are particularly significant [<xref rid="b17-medscimonit-22-810" ref-type="bibr">17</xref>].</p><p>Selective cyclooxygenase (COX)-2 inhibitors were developed in response to the demand for NSAIDs with less AEs. These agents mainly inhibited COX-2 enzyme, which catalyzes the synthesis of prostaglandin and participates in inflammatory reaction [<xref rid="b18-medscimonit-22-810" ref-type="bibr">18</xref>], while COX-1 was preserved to protect the integrity of the GI mucosa [<xref rid="b18-medscimonit-22-810" ref-type="bibr">18</xref>]. Selective COX-2 inhibitors have similar effects on analgesia and anti-inflammatory effects as do non-selective NSAIDS, but the GI tract adverse effects are greatly reduced [<xref rid="b17-medscimonit-22-810" ref-type="bibr">17</xref>,<xref rid="b19-medscimonit-22-810" ref-type="bibr">19</xref>]. Etoricoxib is a very effective selective COX-2 inhibitor for treating acute gout [<xref rid="b14-medscimonit-22-810" ref-type="bibr">14</xref>&#x02013;<xref rid="b16-medscimonit-22-810" ref-type="bibr">16</xref>].</p><p>On the other hand, some authors suggested that systemic corticosteroids might be a safe alternative, particularly in elderly people [<xref rid="b9-medscimonit-22-810" ref-type="bibr">9</xref>,<xref rid="b11-medscimonit-22-810" ref-type="bibr">11</xref>]. A trial has shown that oral prednisolone 35 mg qd for 5 days was well tolerated, and had the same efficacy as naproxen 500 mg bid for the management of acute gout [<xref rid="b20-medscimonit-22-810" ref-type="bibr">20</xref>]. This finding was consistent with the results of another randomized double-blind study [<xref rid="b13-medscimonit-22-810" ref-type="bibr">13</xref>] showing that prednisolone plus paracetamol was as effective as indomethacin plus paracetamol in patients with gout.</p><p>So far, previous studies compared the effects of prednisolone with indomethacin and etoricoxib with indomethacin, but there is no study comparing these three drugs for treating AGA. Therefore, the aim of the present randomized, open-label, active-comparator, controlled trial was to compare the analgesic efficacy, anti-inflammatory efficacy, and tolerability of prednisolone 35 mg qd, indomethacin 50 mg tid, and etoricoxib 120 mg qd for the treatment of AGA.</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><sec sec-type="methods"><title>Study design</title><p>This was an open-label, randomized, controlled, parallel-group trial in patients with AGA to compare the efficacy and safety of prednisolone, etoricoxib, and indomethacin in the treatment of AGA. The study was carried out at the Department of Endocrinology of Nanfang Hospital affiliated to Southern Medical University between April 2015 and August 2015. The study was on the approval of the ethical committee of the Nanfang Hospital affiliated to Southern Medical University. All the patients signed the informed consent. The study was registered at the Chinese Clinical Trials Register (#ChiCTR-IPR-15006269)</p></sec><sec sec-type="subjects"><title>Patients</title><p>One hundred and fifty inpatients aged &#x02265;18 years with AGA within 72 h of onset were consecutively screened. These patients were diagnosed with gout according to the clinical criteria of the 1977 American College of Rheumatology classification criteria [<xref rid="b21-medscimonit-22-810" ref-type="bibr">21</xref>].</p><p>Inclusion criteria were: 1) gout attacks within 72 h of screening; 2) The degree of pain in the index joint was at least moderate (2 on a 5-point Likert scale) at baseline; and 3) the index joint was defined as the joint that was the most painful at the time of randomization. Exclusion criteria were: 1) chronic gouty arthritis stage; 2) clinical suspicion of joint infection or other joint disease; 3) polyarticular gout involving more than four joints; 4) coronary heart disease, heart failure, gastrointestinal hemorrhage, or a history of peptic ulcer; 5) the digestive tract operation history, inflammatory bowel disease, or malignant tumor; 6) using NSAIDs or corticosteroids within 72 h before the baseline assessments; 7) allergic to any of the study drugs; 8) abnormal liver function with transaminase levels higher than 2 times the upper limit of normal; or 9) renal insufficiency with serum creatinine levels greater than 200 &#x003bc;mol/L.</p><p>One hundred-thirty-two patients were randomly assigned (using computer-generated tables and sequential sealed envelopes prepared by a statistician independent to the trial) to receive either prednisolone (35 mg qd, Tianjin Lisheng Pharmaceutical Co., Ltd., Shenzhen, China; n=41), etoricoxib (120 mg qd, Merck Frost, Montreal, Canada; n=46), or indomethacin (50 mg tid, Jiangsu Nhwa Pharmaceutical Co., Ltd., Xuzhou, China; n=45).</p><p>Because AGA is self-limiting, only the first 4 days of treatment was analyzed for drug efficacy. Assessment of pain intensity at baseline was performed without the use of analgesic therapy. All patients were followed up by the same physician who observed and studied them during the 4 days. This study allowed patients to continue (without dose change) low-dose aspirin (&#x02264;100 mg daily) and if patients had used allopurinol for at least 4 weeks, they were allowed to continue its use.</p></sec><sec><title>Endpoints</title><p>The primary endpoint was the reduction of pain in the index joint as experienced by the patient. Secondary endpoints included the changes of physician&#x02019;s assessment of tenderness, erythema, swelling and joint activity from baseline, and also included the patients&#x02019; global assessment of response to therapy. Safety was assessed by observing AEs.</p><p>The degree of pain in the index joint was represented by a 5-point Likert scale (0=none, 1=mild, 2=moderate, 3=severe, 4=extreme) recorded by the patients in a diary at baseline [before start of treatment on Day 1 (h 0)], and probably 4 h after the first dose of drugs on days 2 to 4. The physician evaluated the following indicators: joint tenderness on palpation or passive movement of the index joint (3-point Likert scale: 0=no pain, 1=patient states &#x02018;there is pain&#x02019;, 2=patient states &#x02018;there is pain&#x02019; and withdraws his affected limbs), joint erythema (3-point Likert scale: 0=absent, 1=not assessable, 3=present), joint swelling (4-point Likert scale: 0=no swelling, 1=palpable, 2=visible, 3=bulging beyond the joint margins) and joint activity (4-point Likert scale: 0=no restriction, 1=moderately restricted, 2=significantly restricted, not engaging in general activities, 3=unbearable, cannot take care of themselves) at baseline and at follow-up visits. The physician also assessed patients&#x02019; global response to treatment on a 5-point Likert scale (0=very good, 1 =good, 2=fair, 3= poor, 4= very poor) at the end of the study on Day 4.</p></sec><sec><title>Adverse effects</title><p>AEs during treatment were recorded. AEs mainly included gastric or abdominal pain, dizziness, edema, fatigue or drowsiness, and dry mouth.</p><p>The recurrence of gouty arthritis was diagnosed according to the 1977 American College of Rheumatology classification criteria [<xref rid="b21-medscimonit-22-810" ref-type="bibr">21</xref>]. The degree of pain in the index joint had to be at least mild (2 on a 5-point Likert scale).</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>SPSS 20.0 for Windows (IBM, Armonk, NY, USA) was used for analysis. For baseline characteristic data in the three groups, normally distributed data are presented as the mean &#x000b1; standard deviation (SD) and were tested using one-way ANOVA. Non-normally distributed data are presented as median (range) and were analyzed using the Kruskall-Wallis test. The chi-square test was used for frequencies analysis. For repeated measure data (pain, tenderness, erythema, swelling, and activity), a general linear model was chosen to observe each of the outcome variables (pain, tenderness, erythema, swelling, and activity) across changing time points to determine the treatment effects within and between groups. Significance was defined as a P&#x0003c;0.05.</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="intro|subjects"><title>Characteristics of the patients</title><p><xref ref-type="fig" rid="f1-medscimonit-22-810">Figure 1</xref> presents the patients&#x02019; flowchart: 132 patients were randomized, and 113 patients were finally analyzed. The baseline demographic and clinical characteristics were similar in the 3 groups, except for joint swelling (<xref ref-type="table" rid="t1-medscimonit-22-810">Table 1</xref>).</p></sec><sec><title>Treatment efficacy</title><p><xref ref-type="fig" rid="f2-medscimonit-22-810">Figure 2</xref> show that all 3 drugs significantly decreased the symptoms of acute gout attack in time&#x02014;patients&#x02019; assessment of pain (P&#x0003c;0.05, <xref ref-type="fig" rid="f2-medscimonit-22-810">Figure 2A</xref>), physician&#x02019;s assessment of tenderness (P&#x0003c;0.05, <xref ref-type="fig" rid="f2-medscimonit-22-810">Figure 2B</xref>), erythema (P&#x0003c;0.05, <xref ref-type="fig" rid="f2-medscimonit-22-810">Figure 2C</xref>), swelling (P&#x0003c;0.05, <xref ref-type="fig" rid="f2-medscimonit-22-810">Figure 2D</xref>), and activity (P&#x0003c;0.05, <xref ref-type="fig" rid="f2-medscimonit-22-810">Figure 2E</xref>).</p><p>Results showed that oral prednisolone, etoricoxib, and indomethacin were similar in the efficacy of reducing pain (P&#x0003e;0.05, <xref ref-type="table" rid="t2-medscimonit-22-810">Table 2</xref>) and tenderness (P&#x0003e;0.05, <xref ref-type="table" rid="t2-medscimonit-22-810">Table 2</xref>) in AGA over 4 days. In terms of relieving inflammation, oral prednisolone, etoricoxib, and indomethacin were similar in the efficacy of reducing erythema (P&#x0003e;0.05, <xref ref-type="table" rid="t2-medscimonit-22-810">Table 2</xref>). However, prednisolone might be more effective to reduce swelling compared with indomethacin (P&#x0003c;0.05, <xref ref-type="table" rid="t2-medscimonit-22-810">Table 2</xref>). The 3 drugs were equally effective in improvement of joint activity (P&#x0003e;0.05, <xref ref-type="table" rid="t2-medscimonit-22-810">Table 2</xref>). The patients&#x02019; global response to therapy were similar among the 3 groups (P&#x0003e;0.05, <xref ref-type="table" rid="t3-medscimonit-22-810">Table 3</xref>).</p></sec><sec><title>Recurrence and adverse effects</title><p>There was no significant difference in the recurrence rate 1 month later among the 3 treatment groups (P&#x0003e;0.05, <xref ref-type="table" rid="t4-medscimonit-22-810">Table 4</xref>). Total AEs in the indomethacin group were significantly more frequent compared with the other 2 groups (P&#x0003c;0.05, <xref ref-type="table" rid="t4-medscimonit-22-810">Table 4</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The purpose of the present study was to compare the efficacy and safety of prednisolone, etoricoxib, and indomethacin in the treatment of pain and inflammation in AGA. Results showed that oral prednisolone, etoricoxib, and indomethacin were similar in the efficacy of improving pain, tenderness, and joint activity in AGA over 4 days. For inflammation, oral prednisolone, etoricoxib, and indomethacin were similar in the efficacy of relieving erythema, but prednisolone might be more effective to reduce swelling compared with indomethacin. The patients&#x02019; evaluation of response to treatment efficacy was similar in the 3 groups. There were more AEs with indomethacin compared with the 2 other drugs. These results suggest that each treatment was as effective as the others, and that the choice of a treatment should be made based on each patient&#x02019;s condition and comorbidities.</p><p>The 2012 ACR guidelines [<xref rid="b11-medscimonit-22-810" ref-type="bibr">11</xref>] propose the single use of NSAIDs, systemic corticosteroids, and oral colchicine, but without priority of 1 drug over the others, and recommend that physicians choose the drug based on patient preference, previous treatment reaction, and complications. However, since the therapeutic and toxic doses are very similar, colchicine easily leads to AEs [<xref rid="b9-medscimonit-22-810" ref-type="bibr">9</xref>]. Therefore, in the present study, colchicine was not selected as a study drug.</p><p>Instead, we selected 2 NSAIDs as the study drugs. One was etoricoxib, which has been confirmed with excellent efficacy in the acute phase of gout [<xref rid="b14-medscimonit-22-810" ref-type="bibr">14</xref>&#x02013;<xref rid="b16-medscimonit-22-810" ref-type="bibr">16</xref>], and the other is the criterion standard drug, indomethacin. Oral administration of high doses of NSAIDs is recommended as the first-line therapy for AGA [<xref rid="b11-medscimonit-22-810" ref-type="bibr">11</xref>]. Results showed that etoricoxib had an equal efficacy with indomethacin, indicating that a selective, potent, and rapid COX-2 inhibitor is effective enough to treat AGA, which has been confirmed in several previous studies [<xref rid="b14-medscimonit-22-810" ref-type="bibr">14</xref>&#x02013;<xref rid="b16-medscimonit-22-810" ref-type="bibr">16</xref>].</p><p>The drawbacks of NSAIDs are especially important in patients with gout because these patients are already at high risk of GI tract adverse effects [<xref rid="b22-medscimonit-22-810" ref-type="bibr">22</xref>]. Indeed, most of them are middle-aged or elderly [<xref rid="b23-medscimonit-22-810" ref-type="bibr">23</xref>], and many have comorbidities, such as renal and cardiovascular diseases [<xref rid="b24-medscimonit-22-810" ref-type="bibr">24</xref>,<xref rid="b25-medscimonit-22-810" ref-type="bibr">25</xref>]. In the indomethacin group, 30.6% of patients experienced AEs, but in the etoricoxib group only 6.8% of patients experienced AEs, showing that although both drugs are NSAIDS, the safety of etoricoxib is significantly better than that of indomethacin.</p><p>The efficacy of prednisolone in reducing pain was comparable to indomethacin after 4 days of treatment. In terms of reducing joint swelling, the effect of prednisolone was significantly better than that of indomethacin, which implies that prednisolone may be better at reducing inflammation than indomethacin. Corticosteroids have a significant non-specific inhibition role on the inflammation caused by various factors and in various stages. Some studies [<xref rid="b13-medscimonit-22-810" ref-type="bibr">13</xref>,<xref rid="b20-medscimonit-22-810" ref-type="bibr">20</xref>] have confirmed that the early use of prednisolone can quickly relieve the symptoms and signs of acute attacks, and that it is a safe, effective, and inexpensive method of treatment. In a study [<xref rid="b13-medscimonit-22-810" ref-type="bibr">13</xref>], the prednisolone group patients used slightly more acetaminophen as an adjunct for reducing pain, showing that prednisolone alone may lack enough efficacy to relieve pain in AGA. However, in the present study, the effects on pain relief were similar between the 2 drugs.</p><p>Generally, physicians have reservations about the use of prednisone, for several reasons. Usually, physicians with more experience use NSAIDs to treat AGA. In addition, the long-term use of corticosteroids may cause many AEs, such as Cushing syndrome, diabetes mellitus, hypertension, and osteoporosis. Corticosteroids can only cause severe AEs when used long-term at high doses; if they are taken in low to moderate doses for short periods, few AEs occur. The GI tract AEs of prednisone also appear to be less severe than those of NSAIDs [<xref rid="b26-medscimonit-22-810" ref-type="bibr">26</xref>]. Long-term AEs, such as diabetes mellitus and osteoporosis, are not related to AGA treatment, due to the very short treatment time. In the present study, the AE incidence rate in the prednisolone group (6.1%) was significantly lower than in the indomethacin group (30.6%), consistent with a previous study [<xref rid="b13-medscimonit-22-810" ref-type="bibr">13</xref>].</p><p>The present study is not without limitations. First, the sample size was small and from a single center. Second, the diagnosis was mainly made based on clinical symptoms, and in most patients, joint aspiration or ultrasound examination was not performed. In routine clinical practice, however, most patients presenting with gout-like arthritis are treated according to clinical symptoms but not joint aspiration, unless there is a high suspicion of infectious arthritis or in cases with atypical features. Third, we only observed the first 4 days of drug treatment. Because AGA is self-limited, this design focused the efficacy of drugs on the initial days of the attack, and avoided the impact of spontaneous remission, which could interfere with the efficacy analysis. Finally, we selected patients within 72 h of onset, and most within 48 h. However, the 2012 ACR guidelines [<xref rid="b11-medscimonit-22-810" ref-type="bibr">11</xref>] recommend that AGA should be treated within 24 h after onset. However, patients&#x02019; reluctance to go to the hospital and to pay medical fees may play a role in patients presenting more than 24 h after symptom onset, as well as patients living far from the hospital.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In conclusion, efficacy was comparable among prednisolone, etoricoxib, and indomethacin in treating AGA. Prednisolone might be more effective in reducing inflammation and was better tolerated.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge the invaluable participation of the patients.</p></ack><fn-group><fn id="fn8-medscimonit-22-810"><p><bold>Conflict of interest</bold></p><p>All authors declare that they have no conflict of interest.</p></fn><fn id="fn9-medscimonit-22-810"><p><bold>Source of support:</bold> Departmental sources</p></fn></fn-group><ref-list><title>References</title><ref id="b1-medscimonit-22-810"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KY</given-names></name><name><surname>Ralph Schumacher</surname><given-names>H</given-names></name><name><surname>Hunsche</surname><given-names>E</given-names></name><etal/></person-group><article-title>A literature review of the epidemiology and treatment of acute gout</article-title><source>Clin Ther</source><year>2003</year><volume>25</volume><issue>6</issue><fpage>1593</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">12860487</pub-id></element-citation></ref><ref id="b2-medscimonit-22-810"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>E</given-names></name><name><surname>Hoy</surname><given-names>D</given-names></name><name><surname>Cross</surname><given-names>M</given-names></name><etal/></person-group><article-title>The global burden of gout: estimates from the Global Burden of Disease 2010 study</article-title><source>Ann Rheum Dis</source><year>2014</year><volume>73</volume><issue>8</issue><fpage>1470</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">24590182</pub-id></element-citation></ref><ref id="b3-medscimonit-22-810"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>KM</given-names></name><name><surname>Cameron</surname><given-names>JS</given-names></name><name><surname>Snaith</surname><given-names>M</given-names></name><etal/></person-group><article-title>British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout</article-title><source>Rheumatology (Oxford)</source><year>2007</year><volume>46</volume><issue>8</issue><fpage>1372</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">17522099</pub-id></element-citation></ref><ref id="b4-medscimonit-22-810"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandell</surname><given-names>BF</given-names></name></person-group><article-title>Clinical manifestations of hyperuricemia and gout</article-title><source>Cleve Clin J Med</source><year>2008</year><volume>75</volume><issue>Suppl 5</issue><fpage>S5</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18822469</pub-id></element-citation></ref><ref id="b5-medscimonit-22-810"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggebeen</surname><given-names>AT</given-names></name></person-group><article-title>Gout: an update</article-title><source>Am Fam Physician</source><year>2007</year><volume>76</volume><issue>6</issue><fpage>801</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17910294</pub-id></element-citation></ref><ref id="b6-medscimonit-22-810"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richette</surname><given-names>P</given-names></name><name><surname>Bardin</surname><given-names>T</given-names></name></person-group><article-title>Gout</article-title><source>Lancet</source><year>2010</year><volume>375</volume><issue>9711</issue><fpage>318</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">19692116</pub-id></element-citation></ref><ref id="b7-medscimonit-22-810"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terkeltaub</surname><given-names>RA</given-names></name></person-group><article-title>Clinical practice</article-title><source>Gout N Engl J Med</source><year>2003</year><volume>349</volume><issue>17</issue><fpage>1647</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">14573737</pub-id></element-citation></ref><ref id="b8-medscimonit-22-810"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landis</surname><given-names>RC</given-names></name><name><surname>Haskard</surname><given-names>DO</given-names></name></person-group><article-title>Pathogenesis of crystal-induced inflammation</article-title><source>Curr Rheumatol Rep</source><year>2001</year><volume>3</volume><issue>1</issue><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11177769</pub-id></element-citation></ref><ref id="b9-medscimonit-22-810"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wechalekar</surname><given-names>MD</given-names></name><name><surname>Vinik</surname><given-names>O</given-names></name><name><surname>Moi</surname><given-names>JH</given-names></name><etal/></person-group><article-title>The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors</article-title><source>J Rheumatol Suppl</source><year>2014</year><volume>92</volume><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">25180124</pub-id></element-citation></ref><ref id="b10-medscimonit-22-810"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Jung</surname><given-names>BH</given-names></name><name><surname>Cadet</surname><given-names>P</given-names></name></person-group><article-title>A novel pathway by which the environmental toxin 4-Nonylphenol may promote an inflammatory response in inflammatory bowel disease</article-title><source>Med Sci Monit Basic Res</source><year>2014</year><volume>20</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">24717721</pub-id></element-citation></ref><ref id="b11-medscimonit-22-810"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>D</given-names></name><name><surname>Khanna</surname><given-names>PP</given-names></name><name><surname>Fitzgerald</surname><given-names>JD</given-names></name><etal/></person-group><article-title>2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis</article-title><source>Arthritis Care Res (Hoboken)</source><year>2012</year><volume>64</volume><issue>10</issue><fpage>1447</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">23024029</pub-id></element-citation></ref><ref id="b12-medscimonit-22-810"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terkeltaub</surname><given-names>RA</given-names></name><name><surname>Schumacher</surname><given-names>HR</given-names></name><name><surname>Carter</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator</article-title><source>Arthritis Res Ther</source><year>2013</year><volume>15</volume><issue>1</issue><fpage>R25</fpage><pub-id pub-id-type="pmid">23375025</pub-id></element-citation></ref><ref id="b13-medscimonit-22-810"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Man</surname><given-names>CY</given-names></name><name><surname>Cheung</surname><given-names>IT</given-names></name><name><surname>Cameron</surname><given-names>PA</given-names></name><name><surname>Rainer</surname><given-names>TH</given-names></name></person-group><article-title>Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial</article-title><source>Ann Emerg Med</source><year>2007</year><volume>49</volume><issue>5</issue><fpage>670</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">17276548</pub-id></element-citation></ref><ref id="b14-medscimonit-22-810"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname><given-names>HR</given-names><suffix>Jr</suffix></name><name><surname>Boice</surname><given-names>JA</given-names></name><name><surname>Daikh</surname><given-names>DI</given-names></name><etal/></person-group><article-title>Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis</article-title><source>BMJ</source><year>2002</year><volume>324</volume><issue>7352</issue><fpage>1488</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">12077033</pub-id></element-citation></ref><ref id="b15-medscimonit-22-810"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>SL</given-names></name><name><surname>Dai</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial</article-title><source>Chin Med J (Engl)</source><year>2013</year><volume>126</volume><issue>10</issue><fpage>1867</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">23673101</pub-id></element-citation></ref><ref id="b16-medscimonit-22-810"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>BR</given-names></name><name><surname>Burton</surname><given-names>R</given-names></name><name><surname>Navarra</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><issue>2</issue><fpage>598</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">14872504</pub-id></element-citation></ref><ref id="b17-medscimonit-22-810"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Durme</surname><given-names>CM</given-names></name><name><surname>Wechalekar</surname><given-names>MD</given-names></name><name><surname>Buchbinder</surname><given-names>R</given-names></name><etal/></person-group><article-title>Non-steroidal anti-inflammatory drugs for acute gout</article-title><source>Cochrane Database Syst Rev</source><year>2014</year><volume>9</volume><fpage>CD010120</fpage><pub-id pub-id-type="pmid">25225849</pub-id></element-citation></ref><ref id="b18-medscimonit-22-810"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>DL</given-names></name><name><surname>Botting</surname><given-names>RM</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name></person-group><article-title>Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition</article-title><source>Pharmacol Rev</source><year>2004</year><volume>56</volume><issue>3</issue><fpage>387</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">15317910</pub-id></element-citation></ref><ref id="b19-medscimonit-22-810"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheiman</surname><given-names>JM</given-names></name></person-group><article-title>Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors</article-title><source>Cleve Clin J Med</source><year>2002</year><volume>69</volume><issue>Suppl 1</issue><fpage>SI40</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">12086292</pub-id></element-citation></ref><ref id="b20-medscimonit-22-810"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssens</surname><given-names>HJ</given-names></name><name><surname>Janssen</surname><given-names>M</given-names></name><name><surname>van de Lisdonk</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial</article-title><source>Lancet</source><year>2008</year><volume>371</volume><issue>9627</issue><fpage>1854</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">18514729</pub-id></element-citation></ref><ref id="b21-medscimonit-22-810"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>SL</given-names></name><name><surname>Robinson</surname><given-names>H</given-names></name><name><surname>Masi</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Preliminary criteria for the classification of the acute arthritis of primary gout</article-title><source>Arthritis Rheum</source><year>1977</year><volume>20</volume><issue>3</issue><fpage>895</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">856219</pub-id></element-citation></ref><ref id="b22-medscimonit-22-810"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Underwood</surname><given-names>M</given-names></name></person-group><article-title>Diagnosis and management of gout</article-title><source>BMJ</source><year>2006</year><volume>332</volume><issue>7553</issue><fpage>1315</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">16740561</pub-id></element-citation></ref><ref id="b23-medscimonit-22-810"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>RC</given-names></name><name><surname>Felson</surname><given-names>DT</given-names></name><name><surname>Helmick</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II</article-title><source>Arthritis Rheum</source><year>2008</year><volume>58</volume><issue>1</issue><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">18163497</pub-id></element-citation></ref><ref id="b24-medscimonit-22-810"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersel</surname><given-names>D</given-names></name><name><surname>Schlesinger</surname><given-names>N</given-names></name></person-group><article-title>Treatment of acute gout in hospitalized patients</article-title><source>J Rheumatol</source><year>2007</year><volume>34</volume><issue>7</issue><fpage>1566</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">17610315</pub-id></element-citation></ref><ref id="b25-medscimonit-22-810"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>E</given-names></name><name><surname>Baker</surname><given-names>JF</given-names></name><name><surname>Furst</surname><given-names>DE</given-names></name><name><surname>Schumacher</surname><given-names>HR</given-names></name></person-group><article-title>Gout and the risk of acute myocardial infarction</article-title><source>Arthritis Rheum</source><year>2006</year><volume>54</volume><issue>8</issue><fpage>2688</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">16871533</pub-id></element-citation></ref><ref id="b26-medscimonit-22-810"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia Rodriguez</surname><given-names>LA</given-names></name><name><surname>Hernandez-Diaz</surname><given-names>S</given-names></name></person-group><article-title>The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents</article-title><source>Arthritis Res</source><year>2001</year><volume>3</volume><issue>2</issue><fpage>98</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">11178116</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-medscimonit-22-810" position="float"><label>Figure 1</label><caption><p>Patient flowchart.</p></caption><graphic xlink:href="medscimonit-22-810-g001"/></fig><fig id="f2-medscimonit-22-810" position="float"><label>Figure 2</label><caption><p>(<bold>A</bold>) Mean change in pain of the index joint from baseline (primary endpoint). * P&#x0003c;0.001 <italic>vs.</italic> baseline of the same group. (<bold>B</bold>) Mean change in tenderness of the index joint from baseline. * P&#x0003c;0.001 <italic>vs.</italic> baseline of the same group. (<bold>C</bold>) Mean change in erythema of the index joint from baseline. * P&#x0003c;0.001 <italic>vs.</italic> baseline of the same group. (<bold>D</bold>) Mean change in swelling of the index joint from baseline. The decrease in the swelling index was better with prednisolone than with indomethacin (P=0.01). * P&#x0003c;0.001 <italic>vs.</italic> baseline of the same group. (<bold>E</bold>) Mean change in activity of the index joint from baseline. * P&#x0003c;0.001 <italic>vs.</italic> baseline of the same group.</p></caption><graphic xlink:href="medscimonit-22-810-g002"/></fig><table-wrap id="t1-medscimonit-22-810" position="float"><label>Table 1</label><caption><p>Characteristics of the patients.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Variable</th><th valign="bottom" align="center" rowspan="1" colspan="1">Prednisolone</th><th valign="bottom" align="center" rowspan="1" colspan="1">Etoricoxib</th><th valign="bottom" align="center" rowspan="1" colspan="1">Indomethacin</th><th valign="bottom" align="center" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years, mean&#x000b1;SD)</td><td valign="top" align="center" rowspan="1" colspan="1">44.03&#x000b1;15.37</td><td valign="top" align="center" rowspan="1" colspan="1">44.43&#x000b1;15.08</td><td valign="top" align="center" rowspan="1" colspan="1">43.81&#x000b1;12.29</td><td valign="top" align="center" rowspan="1" colspan="1">0.981</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Men, n (%)</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">100%</td><td valign="top" align="center" rowspan="1" colspan="1">97.2%</td><td valign="top" align="center" rowspan="1" colspan="1">0.343</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">History of gout (years, median (range))</td><td valign="top" align="center" rowspan="1" colspan="1">2.00 (0&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1">2.00 (0&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1">2.00 (0&#x02013;17)</td><td valign="top" align="center" rowspan="1" colspan="1">0.892</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>, mean &#x000b1;SD)</td><td valign="top" align="center" rowspan="1" colspan="1">25.02&#x000b1;2.98</td><td valign="top" align="center" rowspan="1" colspan="1">25.00&#x000b1;3.37</td><td valign="top" align="center" rowspan="1" colspan="1">26.40&#x000b1;2.88</td><td valign="top" align="center" rowspan="1" colspan="1">0.132</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Uric acid (pre-treatment) (&#x003bc;mol/L, mean &#x000b1;SD)</td><td valign="top" align="center" rowspan="1" colspan="1">550.41&#x000b1;122.57</td><td valign="top" align="center" rowspan="1" colspan="1">528.71&#x000b1;135.44</td><td valign="top" align="center" rowspan="1" colspan="1">523.58&#x000b1;118.15</td><td valign="top" align="center" rowspan="1" colspan="1">0.642</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of attacks in past year (median (range))</td><td valign="top" align="center" rowspan="1" colspan="1">2.00 (0.2&#x02013;48)</td><td valign="top" align="center" rowspan="1" colspan="1">1.00 (0.5&#x02013;48)</td><td valign="top" align="center" rowspan="1" colspan="1">1.00 (0&#x02013;48)</td><td valign="top" align="center" rowspan="1" colspan="1">0.814</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Onset time, n (%)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.279</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02264;24 h</td><td valign="top" align="center" rowspan="1" colspan="1">8 (24.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (13.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (16.7%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02264;48 h</td><td valign="top" align="center" rowspan="1" colspan="1">19 (57.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (56.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">24 (66.7%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02264;72 h</td><td valign="top" align="center" rowspan="1" colspan="1">6 (18.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (29.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (16.7%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Index joint</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.839</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Metatasophalangeal joint 1</td><td valign="top" align="center" rowspan="1" colspan="1">13 (39.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (36.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (41.7%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Other foot joints, ankle, or knee</td><td valign="top" align="center" rowspan="1" colspan="1">19 (57.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (61.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (58.3%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Elbow, wrist, or hand</td><td valign="top" align="center" rowspan="1" colspan="1">1 (3.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Patients&#x02019; assessment of pain on baseline, n (%)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.625</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="center" rowspan="1" colspan="1">7 (21.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (38.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (36.1%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Severe</td><td valign="top" align="center" rowspan="1" colspan="1">19 (57.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (36.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (41.7%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Extreme</td><td valign="top" align="center" rowspan="1" colspan="1">7 (21.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (25.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (22.2%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Tenderness, n (%)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.602</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No pain</td><td valign="top" align="center" rowspan="1" colspan="1">1 (3.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (6.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (5.6%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Patient states &#x02018;there is pain&#x02019;</td><td valign="top" align="center" rowspan="1" colspan="1">14 (42.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (47.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (50.0%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Patient states &#x02018;there is pain&#x02019; and withdraws</td><td valign="top" align="center" rowspan="1" colspan="1">18 (54.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (45.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (44.4%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Erythema, n (%)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.972</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Absent</td><td valign="top" align="center" rowspan="1" colspan="1">2 (6.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (4.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (11.1%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Not assessable</td><td valign="top" align="center" rowspan="1" colspan="1">13 (39.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (38.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (30.6%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Present</td><td valign="top" align="center" rowspan="1" colspan="1">18 (54.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (56.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (58.3%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Joint swelling, n (%)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.029</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No swelling</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Palpable</td><td valign="top" align="center" rowspan="1" colspan="1">7 (21.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (34.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (36.1%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Visible</td><td valign="top" align="center" rowspan="1" colspan="1">7 (21.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (29.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (41.7%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bulging beyond joint margins</td><td valign="top" align="center" rowspan="1" colspan="1">19 (57.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (34.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (22.2%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Activity, n (%)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.266</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No restricted</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Moderate restricted</td><td valign="top" align="center" rowspan="1" colspan="1">6 (18.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (25.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (33.3%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Significantly restricted</td><td valign="top" align="center" rowspan="1" colspan="1">12 (36.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (43.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (33.3%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Unbearable, cannot take care of themselves</td><td valign="top" align="center" rowspan="1" colspan="1">15 (45.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (31.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (33.3%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="t2-medscimonit-22-810" position="float"><label>Table 2</label><caption><p>Comparison of the mean changes of patients&#x02019; assessment of pain, physician&#x02019;s assessment of tenderness, erythema, swelling, and activity in the three groups.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Group</th><th valign="bottom" align="center" rowspan="1" colspan="1">Assessment contents</th><th valign="bottom" align="center" rowspan="1" colspan="1">LS mean difference (SE)</th><th valign="bottom" align="center" rowspan="1" colspan="1">95% CI</th><th valign="bottom" align="center" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td valign="middle" rowspan="5" align="left" colspan="1">Prednisolone <italic>vs.</italic> Etoricoxib</td><td valign="top" align="left" rowspan="1" colspan="1">Pain</td><td valign="top" align="center" rowspan="1" colspan="1">0.12 (0.131)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.15 to 0.38</td><td valign="top" align="center" rowspan="1" colspan="1">0.383</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tenderness</td><td valign="top" align="center" rowspan="1" colspan="1">0.11 (0.097)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.08 to 0.31</td><td valign="top" align="center" rowspan="1" colspan="1">0.246</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Erythema</td><td valign="top" align="center" rowspan="1" colspan="1">0.06 (0.111)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.16 to 0.28</td><td valign="top" align="center" rowspan="1" colspan="1">0.586</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Swelling</td><td valign="top" align="center" rowspan="1" colspan="1">0.21 (0.125)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.04 to 0.46</td><td valign="top" align="center" rowspan="1" colspan="1">0.092</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Activity</td><td valign="top" align="center" rowspan="1" colspan="1">0.15 (0.108)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.06 to 0.36</td><td valign="top" align="center" rowspan="1" colspan="1">0.170</td></tr><tr><td valign="middle" rowspan="5" align="left" colspan="1">Prednisolone <italic>vs.</italic> Indomethacin</td><td valign="top" align="left" rowspan="1" colspan="1">Pain</td><td valign="top" align="center" rowspan="1" colspan="1">0.11 (0.138)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.16 to 0.39</td><td valign="top" align="center" rowspan="1" colspan="1">0.415</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tenderness</td><td valign="top" align="center" rowspan="1" colspan="1">0.13 (0.102)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.08 to 0.33</td><td valign="top" align="center" rowspan="1" colspan="1">0.222</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Erythema</td><td valign="top" align="center" rowspan="1" colspan="1">0.11 (0.116)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.12 to 0.34</td><td valign="top" align="center" rowspan="1" colspan="1">0.343</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Swelling</td><td valign="top" align="center" rowspan="1" colspan="1">0.33 (0.131)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 to 0.58</td><td valign="top" align="center" rowspan="1" colspan="1">0.014</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Activity</td><td valign="top" align="center" rowspan="1" colspan="1">0.19 (0.113)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.03 to 0.42</td><td valign="top" align="center" rowspan="1" colspan="1">0.088</td></tr><tr><td valign="middle" rowspan="5" align="left" colspan="1">Etoricoxib <italic>vs.</italic> Indomethacin</td><td valign="top" align="left" rowspan="1" colspan="1">Pain</td><td valign="top" align="center" rowspan="1" colspan="1">0.00 (0.128)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.26 to 0.25</td><td valign="top" align="center" rowspan="1" colspan="1">0.984</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tenderness</td><td valign="top" align="center" rowspan="1" colspan="1">0.01 (0.095)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.18 to 0.20</td><td valign="top" align="center" rowspan="1" colspan="1">0.903</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Erythema</td><td valign="top" align="center" rowspan="1" colspan="1">0.05 (0.108)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.16 to 0.26</td><td valign="top" align="center" rowspan="1" colspan="1">0.645</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Swelling</td><td valign="top" align="center" rowspan="1" colspan="1">0.11 (0.122)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.13 to 0.35</td><td valign="top" align="center" rowspan="1" colspan="1">0.353</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Activity</td><td valign="top" align="center" rowspan="1" colspan="1">0.04 (0.105)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.16 to 0.25</td><td valign="top" align="center" rowspan="1" colspan="1">0.669</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-medscimonit-22-810"><p>SE &#x02013; standard error; CI &#x02013; confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-medscimonit-22-810" position="float"><label>Table 3</label><caption><p>Patients&#x02019; response to treatment.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Patients&#x02019; response to treatment, n (%)</th><th valign="bottom" align="center" rowspan="1" colspan="1">Prednisolone</th><th valign="bottom" align="center" rowspan="1" colspan="1">Etoricoxib</th><th valign="bottom" align="center" rowspan="1" colspan="1">Indomethacin</th><th valign="bottom" align="center" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Very good</td><td valign="top" align="right" rowspan="1" colspan="1">16 (48.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (52.3%)</td><td valign="top" align="right" rowspan="1" colspan="1">16 (44.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.743</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Good</td><td valign="top" align="right" rowspan="1" colspan="1">11 (33.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (34.1%)</td><td valign="top" align="right" rowspan="1" colspan="1">14 (38.9%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fair</td><td valign="top" align="right" rowspan="1" colspan="1">2 (6.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (11.4%)</td><td valign="top" align="right" rowspan="1" colspan="1">3 (8.3%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Poor</td><td valign="top" align="right" rowspan="1" colspan="1">2 (6.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="right" rowspan="1" colspan="1">2 (5.6%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Very poor</td><td valign="top" align="right" rowspan="1" colspan="1">2 (6.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.3%)</td><td valign="top" align="right" rowspan="1" colspan="1">1 (2.8%)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="t4-medscimonit-22-810" position="float"><label>Table 4</label><caption><p>Recurrence and adverse effects.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1"/><th valign="bottom" align="center" rowspan="1" colspan="1">Prednisolone</th><th valign="bottom" align="center" rowspan="1" colspan="1">Etoricoxib</th><th valign="bottom" align="center" rowspan="1" colspan="1">Indomethacin</th><th valign="bottom" align="center" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Recurrence</td><td valign="top" align="center" rowspan="1" colspan="1">17 (52.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (58.1%)</td><td valign="top" align="right" rowspan="1" colspan="1">20 (54.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.621</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total adverse effects</td><td valign="top" align="center" rowspan="1" colspan="1">2/33 (6.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">3/44 (6.8%)</td><td valign="top" align="right" rowspan="1" colspan="1">11/36 (30.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gastric or abdominal pain</td><td valign="top" align="center" rowspan="1" colspan="1">2/33 (6.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="right" rowspan="1" colspan="1">3/36 (8.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.170</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dizziness</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">2/44 (4.5%)</td><td valign="top" align="right" rowspan="1" colspan="1">4/36 (11.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.116</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Edema</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1/44 (2.3%)</td><td valign="top" align="right" rowspan="1" colspan="1">1/36 (2.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.648</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fatigue or drowsiness</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="right" rowspan="1" colspan="1">2/36 (5.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.113</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dry mouth</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="right" rowspan="1" colspan="1">1/36 (2.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.340</td></tr></tbody></table></table-wrap></floats-group></article>